Today’s Stock Alert: Thermo Fisher Scientific Inc Stock Decline in 2016 Q2 Driven by Institutional Investors

November 24, 2016 - By Vivian Park   ·   0 Comments

Today's Stock Alert: Thermo Fisher Scientific Inc Stock Decline in  2016 Q2 Driven by Institutional Investors

Sentiment for Thermo Fisher Scientific Inc (NYSE:TMO)

Thermo Fisher Scientific Inc (NYSE:TMO) institutional sentiment decreased to 0.79 in Q2 2016. Its down -0.18, from 0.97 in 2016Q1. The ratio fall, as 402 hedge funds started new and increased stock positions, while 414 sold and decreased positions in Thermo Fisher Scientific Inc. The hedge funds in our partner’s database now own: 337.36 million shares, down from 353.72 million shares in 2016Q1. Also, the number of hedge funds holding Thermo Fisher Scientific Inc in their top 10 stock positions decreased from 71 to 69 for a decrease of 2. Sold All: 41 Reduced: 373 Increased: 324 New Position: 78.

Thermo Fisher Scientific Inc. develops, makes and sells a range of products. The company has a market cap of $55.46 billion. The Firm is a well-known provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It has a 28.65 P/E ratio. The firm operates through four divisions: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

The stock increased 0.36% or $0.51 on November 23, hitting $143.51. About 2.59 million shares traded hands or 25.73% up from the average. Thermo Fisher Scientific Inc. (NYSE:TMO) has declined 2.27% since April 22, 2016 and is downtrending. It has underperformed by 7.68% the S&P500.

Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on January, 26. They expect $2.38 EPS, up 12.26% or $0.26 from last year’s $2.12 per share. TMO’s profit will be $919.76 million for 15.07 P/E if the $2.38 EPS becomes a reality. After $2.03 actual EPS reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts 17.24% EPS growth.

According to Zacks Investment Research, “Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics. The Company’s four premier brands include Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services. Its portfolio of products includes technologies for mass spectrometry, elemental analysis, molecular spectroscopy, sample preparation, informatics, purity chemistry production, protein analysis, Ribonucleic acid (RNA)-interference techniques, immunodiagnos. Thermo Fisher Scientific Inc. is headquartered in Waltham, Massachusetts.”

Cryder Capital Partners Llp holds 14.81% of its portfolio in Thermo Fisher Scientific Inc. for 124,924 shares. Robecosam Usa Inc. owns 55,135 shares or 10.14% of their US portfolio. Moreover, Monroe Hall Asset Management Llc has 8.44% invested in the company for 205,001 shares. The United Kingdom-based Caledonia Investments Plc has invested 7.57% in the stock. Grand Jean Capital Management Inc, a California-based fund reported 118,913 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 17 insider sales for $37.48 million net activity.

Thermo Fisher Scientific Inc. (NYSE:TMO) Ratings Coverage

Ratings analysis reveals 85% of Thermo Fisher Scientific’s analysts are positive. Out of 13 Wall Street analysts rating Thermo Fisher Scientific, 11 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $140 while the high is $180. The stock’s average target of $156.77 is 9.24% above today’s ($143.51) share price. TMO was included in 27 notes of analysts from July 24, 2015. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Buy” rating by Deutsche Bank on Thursday, January 7. BTIG Research reinitiated the stock with “Buy” rating in Friday, July 22 report. Leerink Swann reinitiated the shares of TMO in a report on Thursday, November 10 with “Outperform” rating. On Tuesday, May 3 the stock rating was maintained by Mizuho with “Buy”. Mizuho maintained the shares of TMO in a report on Thursday, July 23 with “Buy” rating. JP Morgan initiated the shares of TMO in a report on Thursday, September 22 with “Overweight” rating. Barclays Capital maintained the stock with “Overweight” rating in Tuesday, July 19 report. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Neutral” rating by Cleveland on Friday, September 9. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Hold” rating by Jefferies on Friday, April 29. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Buy” rating by Stifel Nicolaus on Monday, January 11.

TMO Company Profile

Thermo Fisher Scientific Inc., incorporated on October 11, 1960, develops, makes and sells a range of products. The Firm is a well-known provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The firm operates through four divisions: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Firm serves its clients through its brands, Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. The Thermo Scientific brand offers clients in research, diagnostics, industrial and applied markets analytical instruments, as well as laboratory equipment, software, services, consumables and reagents.

Another recent and important Thermo Fisher Scientific Inc. (NYSE:TMO) news was published by Wsj.com which published an article titled: “Thermo Fisher Scientific Lifts Outlook” on October 27, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>